- MannKind Corporation is a biopharma company focused on developing and commercializing inhaled therapeutics for endocrinology and lung diseases.
- Mannkind has one FDA-approved inhalable insulin formulation, Afrezza (launched 2015), undergoing a turnaround global-marketing strategy and is also developing a pipeline of eight other therapeutics, two in the clinical phase.
- Mannkind has averaged an 89% 3-year CAGR bringing FYE 19' revenues to $63M with COVID-19 affected estimations for 2020 at $63.7M and an optimistic Afrezza sales influenced estimation for 2021 at $101M(+60%y/y).
- Mannkind's key upcoming catalyst will be Treprostinil Technosphere's Phase 3 wrap-up in Q4 2020 and its FDA filing in 1H 2021.
- In summary, with promising new global sales developments for Afrezza, Treprostinil Technosphere's FDA filing in 1H 2021, and adequate revenue progress thus far, the author projects MannKind Corporation as a "Buy" at a 2-year price target of $2.75 (+34% upside).
For further details see:
MannKind: Global Product Sales, Late-Stage Clinical Pipeline Candidate, And Strong Leadership, 34% Upside